Brief: Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President
01/04/2025 21:06
April 1 (Reuters) - Inhibrx Biosciences Inc INBX.O: INHIBRX BIOSCIENCES ANNOUNCES DEPARTURE OF CSO AND APPOINTMENTS OF NEW CSO AND PRESIDENT INHIBRX BIOSCIENCES INC - APPOINTS CARLOS BAIS AS CSO AND DAVID MATLY AS PRESIDENT INHIBRX BIOSCIENCES INC - BRENDAN ECKELMAN TO ESTABLISH NEW PRIVATE BIOTECH COMPANY AS CEO INHIBRX BIOSCIENCES INC - ENTERS EXCLUSIVE LICENSE AGREEMENT WITH NEW COMPANY Source text: ID:nPn71fyha Further company coverage: INBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibrx Biosciences
See all newsInhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study (updated)
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
NASDAQ RESUMED AT 08:00 AM
Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM